From: Cost-effectiveness of activated protein C in real-life clinical practice
All patients (n = 840) | Survivors (n = 471) | Nonsurvivors (n = 369) | |||||||
---|---|---|---|---|---|---|---|---|---|
Pre-license | Post-license | Pre-Post license difference (95% CI) | Pre-license | Post-license | Pre-Post license difference (95% CI) | Pre-license | Post-license | Pre-Post license difference (95% CI) | |
Omega score | 373 | 427* | 54 (9.12 to 98.03) | 380 | 433 | 53 (-10 to 112) | 364 | 418 | 54 (-13 to 121) |
Reference cost index | 2,430 | 2,862* | 432 (187 to 662) | 2,254 | 2,667*† | 413 (96 to 722) | 2,648 | 3,121*† | 473 (9 to 936) |
ICU stay (day) | 21.3 | 24.4* | 3.1 (0.32 to 5.92) | 23.8 | 26.7† | 2.9 (-0.90 to 6.57) | 18.2 | 21.3† | 3.1 (-0.89 to 7.25) |
Hospital stay (day) | 37.9 | 40.4 | 2.5 (-1.79 to 6.84) | 49.2 | 51.1† | 1.9 (-4.41 to 8.37) | 24.6 | 27.5† | 2.9 (-2.02 to 7.95) |
Costs -rhAPC (€) | 36,717 | 41,144 | 4,427 (-85 to 8,991) | 35,575 | 39,172 | 3,597 (-1,737 to 8,680) | 38,095 | 43,729 | 5,634 (-2,005 to 13,380) |
Total costs (€) | 36,717 | 47,870* | 11,153 (6,601 to 15,709) | 35,575 | 46,752* | 11,177 (5,863 to 16,313) | 38,095 | 49,336* | 11,241 (3,433 to 19,084) |